This page shows you your search results in order of relevance. This is page number 18.
Order by Relevance | Date
Total 290035 results found since Jan 2013.
Gastrointestinal stromal tumour of stomach: Feasibility of laparoscopic resection in large lesions and its long-term outcomes
Conclusion: Our study establishes laparoscopic resection is feasible and safe in treating gastric GISTs for tumours >5 cm size. The long-term disease-free survival in our study shows acceptable oncological results in comparison to historical open resections.
Source: Journal of Minimal Access Surgery - September 16, 2020 Category: Surgery Authors: Parthasarathi Sharma Dhawal Bhushan Chittawadagi Bharath Cumar Saravana Kumar Chinnusamy Palanivelu Source Type: research
Metabolomic and transcriptomic response to imatinib treatment of gastrointestinal stromal tumour in xenograft-bearing mice
CONCLUSIONS: Our multi-omics study confirmed previously known pathways involved in imatinib anticancer activity as well as correlated imatinib-relevant downregulation of expression of purine biosynthesis pathway genes with the reduction of respectful metabolites. Furthermore, considering the importance of the purine biosynthesis pathway for cancer proliferation, we identified a potentially novel mechanism for the anti-tumour activity of imatinib. Based on the results, we hypothesise metabolic modulations aiming at the reduction in purine and pyrimidine pool may ensure higher imatinib efficacy or re-sensitise imatinib-resis...
Source: Translational Oncology - February 12, 2023 Category: Cancer & Oncology Authors: Szymon Macioszek Danuta Dudzik Rafa ł Bartoszewski Tomasz Stokowy Diether Lambrechts Bram Boeckx Agnieszka Wozniak Patrick Sch öffski Micha ł J Markuszewski Source Type: research
Insights into the medical management of gastrointestinal stromal tumours: lessons learnt from a dedicated gastrointestinal stromal tumour clinic in North India
CONCLUSION: Our study is one of the largest comprehensive series describing the clinical and mutational profile of GIST from India. The mutation testing rates at primary care centres continue to be low. Despite the hurdles, a large percentage of our patients underwent molecular testing, aiding in therapeutic decision-making.PMID:36816783 | PMC:PMC9937073 | DOI:10.3332/ecancer.2023.1497
Source: Ecancermedicalscience - February 23, 2023 Category: Cancer & Oncology Authors: Annie Kanchan Baa Sameer Rastogi Sanal Fernandes Shakti Shrivastava Rajni Yadav Adarsh Barwad Shamim A Shamim Nihar Ranjan Dash Source Type: research
